8-K: Gyre Therapeutics: F351 NDA Accepted by China's NMPA

Gyre Therapeutics announces China's NMPA has accepted the New Drug Application for F351 (hydronidone) for treating chronic hepatitis B-induced liver fibrosis.

Summary

• Gyre Therapeutics, Inc. announced on May 12, 2026, that its majority indirectly owned subsidiary, Gyre Pharmaceuticals Co., Ltd., received notification of acceptance of its New Drug Application (NDA) from China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
• The NDA is for F351 (hydronidone), the Company's lead product candidate, for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis.
• This acceptance follows the NMPA's prior granting of priority review status in March 2026.
• F351 is a structurally modified derivative of pirfenidone, designed to target the TGF-β1 signaling pathway.
• Gyre Pharmaceuticals already has a commercialized product, ETUARY (pirfenidone capsule), for IPF in China.
• The company plans to file an Investigational New Drug (IND) application in the U.S. by the end of 2026 for F351 and initiate a Phase 2 clinical trial if the IND becomes effective.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the significant regulatory milestone achieved with the NMPA's acceptance of the NDA for F351, indicating strong progress in a key market.

Positives

• Acceptance of the NDA by China's NMPA for F351 is a significant milestone towards commercialization.
• F351 has received priority review status from the NMPA, indicating potential for an accelerated review process.
• The CDE has shown support for addressing the medical need for liver fibrosis treatments and the potential of F351.
• F351 demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in the PRC.
• F351 received Breakthrough Therapy designation by the CDE of the NMPA in March 2021.
• Gyre Pharmaceuticals has prior experience with NMPA submissions and commercialization in China with ETUARY.

Negatives

• The filing does not contain specific financial metrics or performance data, focusing solely on regulatory progress.
• The company is still in the process of seeking regulatory approval in China and has not yet initiated U.S. clinical trials for F351.

Risks

• Potential delays in the commencement, enrollment, and completion of clinical trials.
• Uncertainties in obtaining successful clinical results for product candidates.
• Risks associated with the inability to obtain sufficient additional capital to advance product candidates.
• Potential failure to realize any value from product candidates being developed.
• Risks associated with the possible failure to realize certain anticipated benefits of the acquisition (referencing Cullgen Inc.).
• Unexpected costs, charges, or expenses.
• Potential adverse reactions or changes to business relationships.

Future Outlook

Gyre Therapeutics plans to file an Investigational New Drug (IND) application in the U.S. by the end of 2026 for F351 and, if the IND becomes effective, to initiate a Phase 2 clinical trial. The company anticipates progressing F351 towards commercial approval in China.

Management Comments

• "This is another significant achievement for Gyre. This NDA is our third submission accepted for review by the NMPA, and the first one for our F351 program."
• "Our interactions with the CDE have been very positive to date, reinforcing the agency's support for addressing the medical need to treat liver fibrosis and the potential of F351 as an innovative therapeutic option."
• "If approved, F351 could address the tens of millions of patients in China with HBV infection, many of whom will develop liver fibrosis and potentially cirrhosis. We look forward to working closely with CDE to progress F351 towards commercial approval."

Industry Context

StockSavvy.ai notes that the acceptance of the NDA for F351 by China's NMPA is a critical step for Gyre Therapeutics in the highly competitive and regulated biopharmaceutical market, particularly in the area of liver fibrosis treatments. This development aligns with the broader industry trend of focusing on unmet medical needs in chronic diseases and leveraging regulatory pathways like priority review to accelerate drug development.

Stakeholder Impact

• Shareholders: Potential for increased company valuation and future revenue if F351 is approved and commercialized.
• Patients: Potential access to a new therapeutic option for CHB-induced liver fibrosis.
• Healthcare Providers: Introduction of a new treatment for liver fibrosis.
• Regulators (NMPA/CDE): Continued engagement in the review and approval process.

Next Steps

• Work closely with the CDE to progress F351 towards commercial approval in China.
• File an Investigational New Drug (IND) application in the U.S. by the end of 2026.
• Initiate a Phase 2 clinical trial in the U.S. if the IND becomes effective.

Key Dates

Recommendation

The acceptance of the NDA is a significant positive step, but commercial approval and U.S. clinical trial initiation are still pending. The company's financial health and ability to fund future development remain key considerations, warranting a 'hold' recommendation until further progress is demonstrated.

Keywords

Gyre Therapeutics, F351, Hydronidone, Liver Fibrosis, Hepatitis B, NDA, NMPA, China